Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Part of paid clinical trials in Decatur, Georgia.

Sponsor
Yale University
Study ID
NCT07040592
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Alcohol Use Disorder (AUD)
  • HIV

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    All participants will receive a prescription for semaglutide and will meet with a clinical pharmacist and addiction psychiatrist for further support

Study Details

This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.

Key Dates

Start date
Jan 15, 2026
Status verified
Mar 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Participants will receive a prescription for semaglutide.

Primary Outcome Measure

Proportion of participants who complete enrollment and duration of sessions [ Time Frame: 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Atlanta VA Medical CenterDecaturGeorgia30033
Ketteria Ingram
[email protected]
407-914-6083
Vincent Marconi, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Decatur, GA

By condition
HIV
By specialty
Infectious disease
By research site
Atlanta VA Medical Center· Decatur, GA

Related Studies